Aggressive R&D Initiatives and Innovative Pipelines - Research Report on J&J, Merck, AbbVie, Novartis, and GSK

NEW YORK, March 7, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Novartis AG (NYSE: NVS), and GlaxoSmithKline Plc (NYSE: GSK). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

Since the beginning of 2013, J&J has already surged 8.3 percent, primarily due to its omnipresence in almost every corner of the health care industry, from pharmaceuticals to medical supplies to personal care products and more. The company's diversity and solid cash flow allows it to withstand pressures. In February, a J&J pharmaceutical company, Janssen Pharmaceutical K.K., announced its submission of a regulatory application to Japanese health authorities seeking approval for simeprevir, administered with pegylated interferon and ribavirin for the treatment of genotype 1 chronic hepatitis C patients. The hepatitis C virus is rampant in Japan, affecting approximately 1.5 to two million people. Furthermore on the pharmaceuticals segment, J&J's prostate cancer drug Zytiga continues to beat expectations, recording over 300 percent sales growth in the previous year, to $961 million. By 2015 the product is expected to reach $1.8 billion. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/aab0_JNJ]

--

Merck & Co., Inc. Research Report

Looking to expand its biologics portfolio, Merck, in agreement with Samsung Bioepis, plans to develop and commercialize multiple pre-specified and undisclosed biosimilar candidates. Through Merck's global commercial presence, combined with Samsung Bioepis' biologic development and manufacturing capabilities, both companies are well positioned to increase access to biosimilars to improve human health. Under the contract, Samsung Bioepis covers the preclinical and clinical development, process development and manufacturing, clinical trials, and registration; and Merck covers the commercialization. The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/d004_MRK]

--

AbbVie Inc. Research Report

Relatively new in the industry, AbbVie was formed in 2013, following emancipation from Abbott Laboratories. On March 1 the company was up 2.41 percent and closed at $37.81. Two years ago, the company was involved in the first well-documented case of an infant who is functionally cured of HIV infection. A drug manufactured by AbbVie was among the treatments prescribed to the Mississippi patient. When the company spun off in January, it also inherited the patents for the co-formulation, which it now markets as Kaletra. According to experts, the treatment is a promising lead for additional R&D toward curing other children. In 2016, patent protection of Kaletra is set to expire. For this year, AbbVie expects to initiate several Phase IIB and Phase III programs. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/2342_ABBV]

--

Novartis AG Research Report

The European Commission has recently approved Ilaris in the treatment of patients with acute gouty arthritis who suffer frequent attacks, and whose symptoms cannot or should not be managed with existing treatment options. Ilaris is the only approved fully human monoclonal antibody targeting IL-1 beta, and is now being investigated in a number of rare inflammatory conditions. Novartis also is taking initiatives to eliminate rheumatic heart disease (RHD) in Zambia, Africa by treating children with streptococcal infections and silent RHD by providing monthly penicillin injections. In February, the company received multiple recognitions for having the most innovative pipeline. The Full Research Report on Novartis AG - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/9659_NVS]

--

GlaxoSmithKline Plc Research Report

ViiV Healthcare, a global specialist HIV company established by GSK and Pfizer, announced a collaboration with the Medicines Patent Pool (MPP), granting MPP a voluntary license for pediatric formulations of the antiretroviral medicine abacavir. To date, ViiV Healthcare has 13 voluntary license agreements with generics companies that facilitate the manufacture and sale of low-cost versions of its medicines. In line with the company's commitment to make its pipeline available through royalty-free voluntary licensing and not-for-profit initiatives, its pipeline products for HIV treatment would be eligible to be licensed to MPP, upon approval of regulatory agencies. The Full Research Report on GlaxoSmithKline Plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/1372_GSK]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers

[email protected]

+1-480-745-7826

SOURCE Investors-Alliance